Study Published in JCI Insight sheds light on the importance of using both transcriptomics and genomics for patient tumor interrogation to gain actionable insight CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized

Findings presented during the developmental therapeutics session at the ASCO 2020 Virtual Scientific Program CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 18, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced the publication of four

NantHealth Announces Eviti Product Updates to Aid Efficiency and Reporting for Payers & NaviNet Product Updates to Enhance the User Experience CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 16, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company,

Providers to benefit from free access to leading payer-provider collaboration platform through May CULVER CITY, Calif. --(BUSINESS WIRE)--May 8, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, will offer free access to the NaviNet AllPayer

    Q1 Financial Highlights 2020 vs 2019: SaaS revenue was $18.1 million , up 2% Total gross margin increased to 60% from 49% Appointed Deanna L. Wise , Senior Vice President and Chief Information Officer for Banner Health , to Board of Directors   Completed Sale of Connected Care Business in

CULVER CITY, Calif. --(BUSINESS WIRE)--May 4, 2020-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2020 first quarter on Thursday, May 7, 2020 , after market close.

New board member brings clinical expertise and IT leadership CULVER CITY, Calif. --(BUSINESS WIRE)-- NantHealth , Inc. ( NASDAQ: NH ), a next-generation, evidence-based, personalized healthcare company, announced today the appointment of Deanna L. Wise , Senior Vice President and Chief Information

Q4 Financial Highlights 2019 vs 2018: Total revenue was $24.2 million , up 6% SaaS revenue was $18.4 million , up 6% Total gross margin increased to 63% from 50% Full-Year Financial Highlights 2019 vs 2018: Total revenue was $96.0 million , up 7% SaaS revenue was $72.8 million , up 11% Total gross

Continued Relationships with Health Insurers Reflect the Need for High-quality, High-value Care as Cancer Treatments Become Increasingly Complex CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 27, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company,

NantHealth Chairman and CEO Will Reveal How Advancements in AI and Machine Learning are Improving the Diagnosis and Treatment of Cancer ORLANDO, Fla. --(BUSINESS WIRE)--Feb. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare technology company,

CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 fourth quarter on Friday, February 28, 2020 , after market close.

Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 19, 2020-- NantOmics, LLC , the leader in molecular

Findings Presented at the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium Orlando, FL and Culver City, CA – February 19, 2020 – NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis, today announced

Culver City, CA — February 4, 2020 :  NantHealth, Inc.  (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare technology company, today announced it has completed the sale of the company’s Connected Care assets to  Masimo , a global leader in noninvasive monitoring technologies

New Partnership to Enable Cost Savings and Rapid ROI Across the Continuum of Care WHEELING, W. Va. & CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 28, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced its partnership with The

Derived from deep-learning models, the findings demonstrate novel AI methods of identifying tumor-infiltrating lymphocytes (TILs) in lung cancers BURLINGAME, Calif. --(BUSINESS WIRE)--Jan. 27, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium SAN FRANCISCO --(BUSINESS WIRE)--Jan. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium SAN FRANCISCO --(BUSINESS WIRE)--Jan. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced new real-world data on treatment patterns for

IRVINE, Calif. & CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2020-- Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies, and NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the signing of a definitive